92 results on '"Haegert, Anne"'
Search Results
2. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma
3. Supplementary Figure 1 from Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target
4. Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
5. Data from Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target
6. Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
7. Supplementary Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
8. Supplementary Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
9. Supplementary Table 5 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
10. Supplementary Table S1 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
11. Supplementary figure S2 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
12. Supplementary Figure 1 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
13. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability
14. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability
15. Supplementary Table 2 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
16. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability
17. Supplementary Table S2 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
18. Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
19. Supplementary Table S3 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
20. Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
21. Supplementary figure S4 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
22. Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
23. Supplementary Table 1 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
24. Supplementary Table S1 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
25. Supplementary figure S3 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
26. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability
27. Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
28. Supplementary figure legends from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
29. Supplementary figure S7 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
30. Supplementary figure S5 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
31. Supplementary figure S6 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
32. Supplementary figure S1 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
33. Supplementary Table 3 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
34. Supplementary Figures 1 - 9 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
35. Data from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
36. Supplementary Table 1 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
37. Supplementary Figures 1 - 9 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
38. Supplementary Table 2 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
39. Data from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
40. Supplementary Table 1 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
41. Supplementary Table 2 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
42. Supplementary Table 3 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
43. Differentiation of Peritubular Myoid‐Like Cells from Human Induced Pluripotent Stem Cells
44. Patient and cell-type specific hiPSC-modeling of a truncating titin variant associated with atrial fibrillation
45. Indwelling stents cause obstruction and induce ureteral injury and fibrosis in a porcine model
46. Isolating Nuclei From Frozen Human Heart Tissue for Single‐Nucleus RNA Sequencing
47. Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
48. Cobalt ions induce metabolic stress in synovial fibroblasts and secretion of cytokines/chemokines that may be diagnostic markers for adverse local tissue reactions to hip implants
49. Ketogenesis controls mitochondrial gene expression and rescues mitochondrial bioenergetics after cervical spinal cord injury in rats
50. Novel Lignin-Capped Silver Nanoparticles against Multidrug-Resistant Bacteria
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.